Search Results
559 results
Your search is now limited to «Novartis» expert search.
pharmaphorum 01/16/2019 07:06
Finally, immuno-oncology company ImmunSYS has appointed the former CEO of Novartis Corporation, Douglas Watson, to its Board of Directors as lead independent director.
More from pharmaphorum:
Forbes 01/16/2019 00:02
We need to bring our best technology – biological and digital – and our most creative people together to work on this monumental challenge. One clear take-away from the Narasimhan interview: pharma is at the very earliest stages of figuring out how to do this.
More from Forbes:
(MENAFN - GetNews) Global Bipolar Disorder Treatment Industry 2018 Market Research Report has been analyzed in detail to assist clients with all the vital data to frame tactical bu...
More from Middle East North Africa Financial Network (MENAFN): 01/15/2019 15:43
Recently, Novartis (NVS) announced that it had received FDA breakthrough Therapy Designation for its sickle cell drug crizanlizumab (SEG101.
More from
Seeking Alpha 01/15/2019 14:35
Recently, Novartis (NVS) announced that it had received FDA breakthrough Therapy Designation for its sickle cell drug crizanlizumab (SEG101.
More from Seeking Alpha:
BioPharma Dive 01/15/2019 10:00
The new House Oversight chairman has asked 12 pharmas for pricing info on 18 top drugs, as Congress prepares to further scrutinize the industry.
More from BioPharma Dive:
PharmaManufacturing 01/10/2019 22:01
Britain's National Institute for Health and Care Excellence (NICE) rejected Novartis’s migraine drug, Aimovig, concluding that the drug was not a cost-effective use of resources.
More from PharmaManufacturing:
FiercePharmaManufacturing 01/10/2019 11:12
Novartis’ Aimovig fails to win NICE backing amid tight migraine fight with Lilly, Teva.
More from FiercePharmaManufacturing:
R&D Magazine 01/10/2019 09:00
Novartis announced an offer to acquire CellforCure from LFB.
More from R&D Magazine:
ENDPOINTS 01/10/2019 08:40
The drug, erenumab, is sold as Aimovig in the United States by Novartis and partner Amgen $AMGN.
More from ENDPOINTS: 01/10/2019 06:10
Novartis, with exclusive rights to the drug in Europe while cooperating with Amgen in the United States, said it was “disappointed” in the National Institute for Health and Care Excellence’s (NICE) conclusion.
More from
BioPharma-Reporter 01/10/2019 05:48
In draft guidance, the UK’s National Institute for Health and Care Excellence (NICE) rejected providing funding for Novartis’ treatment for migraines, Aimovig (erenumab.
More from BioPharma-Reporter:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications